For example, CASC9 promotes gefitinib resistance in non-small cell lung cancer (NSCLC) by recruiting EZH2 (a histone methyltransferase) and inducing the epigenetic repression of DUSP1 (49). Here, PRDM9 is linked to non-small cell lung carcinoma.